Page 7 - Project Bioshield News Today

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

PRINCETON, N.J., Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. SNGX (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Study HPN-PSR-01 opens patient enrollment PRINCETON, N.J., Dec. 19, 2022 /PRNewswire/ -- Soligenix, Inc. SNGX (Soligenix or the Company), a late-stage

Because dual-use biotechnologies developed in the private sectoroffer powerful tools to protect Americans from biological threatsand to increase the military's operational capabilities, thefederal government should promote international liabilityprotection for developing and deploying new national security goodsand services, promote scientific travel and exchanges, and assign alead agency to coordinate biotechnology exploitation for nationalsecurity.

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Community Blood Center/Community Tissue Services is celebrating a historic milestone — the agency distributed a record one million tissue grafts in 2022 alone.

Community Blood Center/Community Tissue Services is celebrating a historic milestone — the agency distributed a record one million tissue grafts in 2022 alone.

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...